Table 1.

Demographic characteristics of the study population based on the receipt of chemotherapy

Variable	Received chemotherapy, n (%) (N = 46 167)	Did not receive chemotherapy, n (%) (N = 15 608)	P
Age, y			<.0001
18-40	6 858 (14.8)	418 (2.7)
41-59	14 280 (30.9)	1 232 (7.9)
60-70	12 194 (26.4)	2 314 (14.8)
71-80	9 480 (20.5)	5 210 (33.4)
≥81	3 355 (7.3)	6 434 (41.2)
Male sex	24 865 (53.9)	8 125 (52.1)	<.0001
Race			<.0001
White	39 719 (86.0)	13 802 (88.4)
African American	4 018 (8.7)	1 211 (7.8)
Other	2 430 (5.3)	595 (3.8)
No high school diploma, %*			.04
≥29	7 608 (16.5)	2 559 (16.4)
20-28.9	10 559 (22.9)	3 642 (23.3)
14-19.9	11 170 (24.2)	3 896 (25.0)
<14	16 830 (36.4)	5 511 (35.3)
Median household income*			<.0001
<$30 000	5 991 (13.0)	2 205 (14.1)
$30 000-$34 999	8 552 (18.5)	3 004 (19.2)
$35 000-$45 999	12 874 (27.9)	4 583 (29.4)
≥$46 000	18 750 (40.6)	5 816 (37.3)
Insurance status			<.0001
Not insured	1 867 (4.0)	376 (2.4)
Private insurance/managed care	20 790 (45.0)	2 679 (17.2)
Medicaid	4 049 (8.8)	478 (3.1)
Medicare	18 915 (41.0)	11 978 (76.7)
Other government	546 (1.2)	97 (0.6)
Charlson comorbidity score			<.0001
0	34 466 (74.7)	9 752 (62.5)
1	8 623 (18.7)	3 729 (23.9)
≥2	3 078 (6.7)	2 127 (13.6)
Distance traveled, miles			<.0001
0-4.9	10 040 (21.7)	5 769 (36.7)
5-11.9	11 401 (24.7)	4 313 (27.6)
12-34.7	12 275 (26.6)	3 294 (21.1)
≥34.8	12 451 (27.0)	2 232 (14.3)
AML subtypes			<.0001
Acute promyelocytic leukemia	4 507 (9.8)	712 (4.6)
Core binding factor AML	1 535 (3.3)	243 (1.6)
Therapy-related AML	701 (1.5)	200 (1.3)
Other intermediate/high risk	39 424 (85.4)	14 453 (92.6)
Receipt of care in academic centers	25 890 (56.1)	4 583 (29.4)	<.0001
Annual hospital volume, median (quartiles) [range]	15 (7-35) [1-122]	7 (4-14) [1-122]	<.0001

^*Based on Zip code.